Barr News (NYSE:BRL)
| Latest Barr Pharma News Headlines | | Date | Time | Source | | | 10/07/2008 | 10:06AM | PRNUS | Barr Will Host An Earnings Conference Call on November 6, 2008 to Discuss the Results for the Third Quarter of Calendar 2008
MONTVALE, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the Company will host a Conference Call at 8:30 AM Eastern time on Thursday, November 6 to discuss earnings results for the third quarter of calendar 2008, ended September 30, 2008. The number to call from within... More...>> |
| 09/25/2008 | 8:00AM | PRNUS | Ready and Willing, but Unable? Survey Reveals Boomers Desire Sex, But Face Physical Challenges
MONTVALE, N.J., Sept. 25 /PRNewswire/ -- While the majority of adults aged 50 to 70 agree that decreased frequency, physical ability to have or desire for sex is expected with age, a recent survey indicates that women were less prepared than men for the physical changes that are often associated with menopause that... More...>> |
| 09/16/2008 | 3:58PM | PRNUS | Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
MONTVALE, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) ER (galantamine... More...>> |
| 09/03/2008 | 2:00PM | PRNUS | Teva and Barr Receive FTC Request for Additional Information
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Barr Pharmaceuticals, Inc. (NYSE:BRL) announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal... More...>> |
| 08/28/2008 | 12:18PM | PRNUS | Barr Receives Approval for Generic Version of Razadyne(R) Tablets
MONTVALE, N.J., Aug. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) (galantamine hydrobromide... More...>> |
| 08/28/2008 | 8:48AM | PRNUS | Barr Announces Favorable Ruling in Razadyne(R) Patent Challenge
MONTVALE, NJ, Aug. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the U.S. District Court for the District of Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of U.S. Patent No. 4,663,318 ("the '318 patent") listed by Ortho McNeil Janssen... More...>> |
| 08/25/2008 | 9:33AM | PRNUS | Barr Confirms Patent Challenge of FazaClo(R) Orally Disintegrating Tablets, 25mg and 100mg
MONTVALE, N.J., Aug. 25 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Azur Pharma International in connection with its FazaClo(R) (clozapine) orally disintegrating tablets, 25mg and 100mg... More...>> |
| 08/21/2008 | 12:26PM | PRNUS | /C O R R E C T I O N -- Barr Pharmaceuticals, Inc. (NYSE: BRL)/
In the news release, Barr Pharmaceuticals, Inc. (NYSE: BRL) Announces Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable, issued yesterday, Aug. 20, by Barr Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that there were the following corrections were made... More...>> |
| 08/20/2008 | 8:19AM | PRNUS | Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable
MONTVALE, N.J., Aug. 20 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Aredia(R) (pamindronate disodium) Injection, 30mg/mL... More...>> |
| 08/12/2008 | 9:00AM | PRNUS | Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges
MONTVALE, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately... More...>> |
| 08/07/2008 | 7:25AM | PRNUS | Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
- Launch of Generic Yasmin(R) Oral Contraceptive Contributes to Higher U.S. Generic Sales
MONTVALE, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today reported net earnings of $57 million, or $0.52 per share, on revenues of $779 million for the quarter ended June 30, 2008. The current... More...>> |
| 07/31/2008 | 11:57AM | PRNUS | Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets
MONTVALE, N.J., July 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg.
The... More...>> |
| 07/29/2008 | 9:10AM | PRNUS | Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
MONTVALE, N.J., July 29 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar(R) Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.
Barr's Abbreviated... More...>> |
| 07/24/2008 | 2:45PM | PRNUS | Barr Confirms Patent Challenge of Fentora(R) Tablets
MONTVALE, N.J., July 24 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Cephalon, Inc. in connection with its Fentora(R) Tablets (fentanyl citrate buccal tablets), equivalent to fentanyl base... More...>> |
| 07/18/2008 | 7:00AM | PRNUS | Teva to Acquire Barr
Significantly Strengthens Teva's Market Leadership Position in the U.S. and in Key Global Markets
JERUSALEM and MONTVALE, N.J., July 18 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Barr Pharmaceuticals, Inc. (NYSE:BRL) announced today that they have signed a definitive agreement under... More...>> |
| 07/03/2008 | 10:10AM | PRNUS | Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008
MONTVALE, N.J., July 3 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that the Company will host a Conference Call at 8:30AM Eastern time on Thursday, August 7 to discuss earnings results for the second quarter of calendar 2008, ended June 30, 2008. The number to call from within the... More...>> |
| 06/26/2008 | 5:20PM | PRNUS | Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge
MONTVALE, N.J., June 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer... More...>> |
| 06/24/2008 | 2:00AM | PRNUS | Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives
- Barr Plans to Launch Generic Yasmin(R) on or before July 1, 2008
MONTVALE, N.J., June 24 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its wholly owned subsidiary, Barr Laboratories, Inc. has entered into supply and licensing agreements with Bayer for generic versions of Bayer's... More...>> |
| 06/10/2008 | 3:34PM | PRNUS | Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
MONTVALE, N.J., June 10 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by TAP Pharmaceuticals Inc. in connection with its Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets... More...>> |
| 05/27/2008 | 4:04PM | PRNUS | Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules
MONTVALE, N.J., May 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by AstraZeneca LP in connection with its Entocort(R) Enteric Coated Capsules (budesonide), 3mg. The Company believes that... More...>> |
|
|
|